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The SOX gene family consists of twenty transcription factors that
play a pivotal role in cell fate and differentiation during the
development of many organ systems. These genes contain a highly
conserved high mobility group (HMG) domain that has been shown
to be critical for DNA binding and bending, nuclear trafficking, and
protein-protein interactions. Mutations within this transcription factor
family have been associated with rare congenital disorders, known
as SOXopathies. These mutations are commonly de novo,
heterozygous and inactivating, and exhibit gene haploinsufficiency.
Of these twenty transcription factors, SOX6 is known to be involved
in chondrocyte differentiation and development of the central
nervous system. Although there have been reports of SOX6
variants causing adult pathological conditions in genome wide
association studies, there has yet to be a well-established
association between SOX6 variants and a developmental
syndrome.
INTRODUCTION RESULTS 
The objective of this study was to use clinical and genetic data to
examine SOX6 variants found in 19 individuals demonstrating
developmental delay and to test the transcriptional activity of the 4
missense variants in vitro to determine if SOX6 haploinsufficiency
leads to a neurodevelopmental SOXopathy.
OBJECTIVES
Nineteen individuals were identified as carriers of SOX6 variants,
confirmed by molecular karyotyping, whole-exome sequencing, or
whole-genome sequencing. Clinical pathogenicity was predicted
and assessed in silico and in vitro.
Expression plasmids for SOX6 missense variants were generated
by PCR mutagenesis. The four missense variants generated were:
p.Trp161Cys, p.Met605Thr, p.Trp639Arg, and p.Ser746Leu, with
p.Met605Thr and p.Trp639Arg located within the HMG domain. For
reporter assays, HEK293 cells were transfected in triplicate cultures
with 3.5 µL ViaFect Transfection Reagent and a total of 1000ng of
DNA. SOX6 intracellular localization was tested by transfecting
either HEK293 or COS-1 cells and cytoplasmic and nuclear extracts
were prepared for Western Blot analysis. Whole cell extracts
transfected with respective WT-SOX6 or variant plasmid were also




Figure 1. Clinical findings in
subjects with SOX6 variants
Patient ages ranged between 12
months and 27 years. Most
individuals had intellectual disability
(18/19) and abnormal behavior
(14/19) such as ADHD (10/19) or
autism spectrum disorders (4/19).
Dysmorphic features and skeletal
anomalies were noted in many
individuals, including mild facial
dysmorphism (Figure 1A). Moreover,
multiple diffuse osteochondromas
were present in three patients
(arrowed in Figure 1B and C).
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Figure 2. Single nucleotide variants (SNVs) identified in patients and their evolutionary
conservation
All SNVs were distinct and corresponded to 4 nonsense, 2 frameshift, and 4 missense
mutations. The nonsense and frameshift variants caused SOX6 truncation encoding a non-
functional protein. The missense variants were in the HMG domain and non-functional
regions (Figure 2A). However, they were all were conserved among the SOXD group (i.e.,
SOX5, SOX6 and SOX13) and the other SOX genes. Additionally, two of the affected





Figure 3. Functional tests
of SOX6 missense variants
All variants were efficiently
expressed after transfection
in HEK cells. p.Met605Thr
and p.Trp639Arg proteins
were not translocated or
retained into the nucleus as
efficiently as WT SOX6
(Figure 3A). In addition,
they failed to bind the DNA
probe in the EMSA and to
transactivate the reporter in
luciferase assays (Figure3B
and C).
On the contrary, pTrp161Cys
and p.Ser746Leu variants
showed normal protein
activity. Finally, none of the




Figure 4. Analysis of SOX6 expression in the human brain
Whole transcriptome profiling data deposited in the Brain-Span Atlas of the Developing Human
Brain provided information on where and when SOX6 is expressed in the brain of human
fetuses, children, and adults. At 9 weeks after conception, fetuses were found to express SOX6
in many prospective brain structures. SOX6 RNA expression was highest in the ganglionic
eminence, the amygdaloid complex, and the hippocampus, all of which have central roles in
brain development (Figure 4A). The expression of SOX6 declined in all brain structures in the
final stages of gestation and in the neonatal period (Figure 4B).
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• The findings from this study concur that SOX6 haploinsufficiency leads to a specific form of neurodevelopmental SOXopathy
characterized by mild to severe intellectual disability and inconstantly associated with skeletal anomalies, such as mild facial
dysmorphism, craniosynostosis, and osteochondromas.
• No clear genotype-phenotype correlations were found.
• This new syndrome has been designated in Online Mendelian Inheritance in Man (OMIM) database as #618971 Tolchin-Le Caignec
syndrome (TOLCAS).
*For the complete list of authors, visit: https://doi.org/10.1016/j.ajhg.2020.04.015 
